FFA
ABCL icon

Farther Finance Advisors’s AbCellera Biologics ABCL Stock Holding History

Farther Finance Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$47.9K Sell
3,283
-3,362
-51% -$31.9K ﹤0.01% 3459
2026
Q2 		$52.2K Sell
6,645
-10,000
-60% -$48.9K ﹤0.01% 3213
2026
Q1 		$58.4K Hold
16,645
– – ﹤0.01% 2885
2025
Q4 		$56.9K Hold
16,645
– – ﹤0.01% 2727
2025
Q3 		$83.7K Buy
16,645
+752
+5% +$3.31K ﹤0.01% 2141
2025
Q2 		$54.5K Hold
15,893
– – ﹤0.01% 2097
2025
Q1 		$33.2K Hold
15,893
– – ﹤0.01% 2115
2024
Q4 		$46.6K Sell
15,893
-606
-4% -$1.69K ﹤0.01% 1698
2024
Q3 		$42.9K Buy
16,499
+1,487
+10% +$4.12K ﹤0.01% 1737
2024
Q2 		$41.7K Hold
15,012
– – ﹤0.01% 1495
2024
Q1 		$66.7K Buy
15,012
+5,000
+50% +$25.5K ﹤0.01% 1087
2023
Q4 		$57.2K Buy
+10,012
New +$46.4K ﹤0.01% 991

Other funds holding ABCL

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
DWM
DKM Wealth Management Stockton, California $158M AUM 11.62% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return

Farther Finance Advisors's ABCL Position: Q3 2026 in Review

Farther Finance Advisors reduced its AbCellera Biologics (ABCL) stake by 51% in Q3 2026, selling an estimated $31.9K and leaving 3,283 shares worth $47.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3459.

Farther Finance Advisors first reported a position in ABCL in Q4 2023 and has held it in 12 quarters since. The position peaked at $83.7K in Q3 2025. 4 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Farther Finance Advisors held 3,283 shares of AbCellera Biologics worth $47.9K as of Q3 2026.
  • Farther Finance Advisors sold 3,362 AbCellera Biologics shares in Q3 2026, an estimated $31.9K.
  • AbCellera Biologics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3459 holding.
  • Farther Finance Advisors first reported a position in AbCellera Biologics in Q4 2023 and has held it in 12 quarters since.
  • Farther Finance Advisors's AbCellera Biologics position peaked at $83.7K in Q3 2025.
  • 4 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.